Q Line Biotech
MAINBOARD
Listed
Price Band
₹343
Lot Size
42 Shares
Issue Size
₹85.00 Cr
Fresh Issue
₹63.75 Cr
OFS
₹21.25 Cr
Registrar
AI Sentiment Score
Listing Price
₹452.00
vs Issue: ₹343 (+31.78%)
📅 IPO Timeline
✓
Open
May 22, 2026
✓
Close
May 24, 2026
✓
Allotment
May 26, 2026
✓
Refund
May 27, 2026
✓
Demat
May 27, 2026
✓
Listing
May 29, 2026
📈 Grey Market Premium (GMP) Trendline
Daily consensus GMP movement (₹) recorded across market sources
✨ AI Analysis & Prediction
🔒 Final Reconciled Estimate
Locked post-listing with actual debut performance
Q Line Biotech displays an established operational footprint with expanding revenue streams (23.2% CAGR) and a defensible value proposition.
💪 Strengths
- Demonstrated operational revenue trajectory with resilient top-line growth (23.2% CAGR).
- Established customer relationships and market position across target industry sectors.
- Sound operational capital returns with Return on Capital Employed (ROCE) at 22.4%.
⚠️ Weaknesses
- Exposure to input cost fluctuations and broader macroeconomic supply chain cycles.
- Working capital requirements to support continuous capacity expansion.
- Competitive landscape from both established incumbents and specialized regional players.
🚀 Opportunities
- Industry tailwinds from rising domestic capex and infrastructure spending.
- Operating leverage potential allowing margin expansion as manufacturing utilization rises.
- Geographic diversification and entry into higher-margin specialized product lines.
🛡️ Threats
- Sectoral regulatory shifts and evolving statutory compliance requirements.
- Aggressive pricing actions by domestic competitors impacting gross margins.
- Broader market equity volatility and liquidity fluctuations.
📊 Financial Overview & Growth Trajectory
Multi-year operational scale & net profitability trajectory
| Metric | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|
| Revenue (₹ Cr) | Rs 183.00 Cr | Rs 203.00 Cr | Rs 313.00 Cr | Rs 342.00 Cr |
| Net Profit / PAT (₹ Cr) | Rs 32.00 Cr | Rs 34.00 Cr | Rs 19.00 Cr | Rs 56.00 Cr |
| EBITDA / Op. Profit (₹ Cr) | Rs 34.00 Cr | Rs 38.00 Cr | Rs 71.00 Cr | Rs 98.00 Cr |
| Borrowings (₹ Cr) | Rs 74.00 Cr | Rs 97.00 Cr | Rs 166.00 Cr | Rs 225.00 Cr |
| Total Assets (₹ Cr) | Rs 252.00 Cr | Rs 339.00 Cr | Rs 455.00 Cr | Rs 559.00 Cr |
| ROE % | 0.00% | 0.00% | 0.00% | 0.00% |
| ROCE % | 22.40% | 22.40% | 22.40% | 22.40% |
| Debt / Equity | 0.00 | 0.00 | 0.00 | 0.00 |
Company P/E
27.1x
Industry P/E
31.2x
Debt/Equity
0.91
⚖️ Valuation Benchmark Range
🟢 Attractively Priced vs Industry Peers
Industry 31.2x
IPO 27.1x
0x (Deep Value)
42x (High Multiple)
📋 Live Subscription Status
QIB
4.15x
NII
3.98x
Retail
2.93x
Total
3.51x
🎯 Retail Allotment Probability
34.1% Odds
1 in 2.9 chance (~34.1% probability per PAN)
SEBI Rule: Under SEBI lottery allotment rules, applying for multiple lots under Retail does NOT increase your lottery odds. All valid retail applicants have identical 1-lot odds per PAN.
Updated: Sep 12, 2026 2:32 PM
💼 Issue Structure & Reservation Quota
Capital Structure
₹85.0 Cr
Issue Size
Fresh (75%)
OFS (25%)
Reservation Quota
100%
Allocation
QIB (50%)
NII (15%)
Retail (35%)
QIB
50.00%
Retail
35.00%
NII
15.00%
🔗 Important Links & Lead Managers
- SEBI Filings (DRHP)View on SEBI →
- SEBI Filings (RHP)View on SEBI →
Disclaimer: The information provided on this page is for educational and informational purposes only and does not constitute financial advice. IPO investments are subject to market risks. AI-generated analysis is based on publicly available data and may not be accurate. Grey Market Premium (GMP) is unofficial and highly speculative. Always consult a qualified financial advisor and read the DRHP/RHP carefully before making investment decisions.